Sees FY24 Humira sales $9.6B. Says expects economic headwinds for aesthetic portfolio to continue in China in the near term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, February 02, 2024
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- ABBV Earnings this Week: How Will it Perform?
- Palo Alto downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
